 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 1 
  1 
 2 
 3 
  4 
The International Diabetes Closed Loop (iDCL) trial: [ADDRESS_155914] of t:slim X2 with Control -IQ Technology  8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
Version 1.0 17 
October 16 , 2017 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
Protocol Chair 34 
Sue Brown, M.D., University of Virginia   35 
 36 
Participating Institutions  37 
University of Virginia, Charlottesville, VA  38 
 39 
Coordinating Center 40 
University of Virginia, Charlottesville, VA  41 
 42 
 43 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 2 
 TABLE OF CONTENTS  44 
 45 
CHAPTER 1:  INTRODUCTION  ................................................................................................. 5  46 
1.1. Background and Rationale .................................................................................................. 5  47 
1.2. Synopsis of Study Protocol ................................................................................................. 7  48 
1.2.1.  Study Objective  ................................................................................................................... 7  49 
1.2.2.  Major Eligibility Criteria  .................................................................................................... 7  50 
1.2.3.  Sample Size  ......................................................................................................................... 7  51 
1.2.4.  Protocol Summary .............................................................................................................. 7  52 
1.2.5.  Outcomes  ............................................................................................................................ 8  53 
1.3. General Considerations ....................................................................................................... 8  54 
CHAPTER 2:  VISIT 1:  SUBJECT SCREENING AND ENROLLMENT  ............................. 18  55 
2.1. Study Population ............................................................................................................... 18  56 
2.2. Eligibility and Exclusion Criteria  ..................................................................................... 18  57 
2.2.1.  Eligibility  .......................................................................................................................... 18  58 
2.2.2.  Exclusion .......................................................................................................................... 18  59 
2.3. Authorization Procedures ................................................................................................. 19  60 
2.4. Screening and Enrollment Visit Logistics  ........................................................................ 19  61 
2.4.1.  Data Collection and Testing  ............................................................................................. 19  62 
CHAPTER 3:  VISIT 2:  36-48- HOUR SUPERVISED STUDY ............................................... 21  63 
3.1. Timing  ............................................................................................................................... 21  64 
3.2. Procedures upon Arrival to the Study Site ........................................................................ 21  65 
3.3. Study Device Initiation and Training ................................................................................ 21  66 
3.4. Procedures during Study ................................................................................................... 22  67 
3.5. Procedures for Monit oring  ................................................................................................ 22  68 
3.6 Qualifications and Role of the Staff ................................................................................. 23  69 
3.7 Visit 3: Follow-up Visit .................................................................................................... 23  70 
CHAPTER 4:  SAFETY MEASURES  ........................................................................................ 24  71 
4.1 Safety Measures  ................................................................................................................ 24  72 
4.1.1  CGM Calibration  .............................................................................................................. 24  73 
4.1.2  Insulin Dosing ................................................................................................................... 24  74 
4.1.3  Hypoglycemia Safety Protocol  ......................................................................................... 24  75 
4.1.4  Hyperglycemia Safety Protocol ........................................................................................ 24  76 
4.1.5  Study Data Monitoring  ..................................................................................................... 25  77 
4.1.6  CGM Sensor Connection Failure ...................................................................................... 25  78 
4.1.7  Control-IQ Connection Failure ......................................................................................... 25  79 
4.1.8  Study Syste m Failure  ........................................................................................................ 25  80 
CHAPTER 5:  ADVERSE EVENTS, DEVICE ISSUE S, POTENTIAL RISKS, AND 81 
STOPPI[INVESTIGATOR_16442]  ...................................................................................................................... 26  82 
5.1 Adverse Event Definition  ................................................................................................. 26  83 
5.2 Recording of Adverse Events  ........................................................................................... 26  84 
5.3 Reporting Serious Adverse Events or Unexpected Adverse Device Effects  .................... 27  85 
5.4 Device Issues  .................................................................................................................... 28  86 
5.5 Medical Monitor ............................................................................................................... 28  87 
5.6 Potential Risks and Side Effects  ....................................................................................... 28  88 
5.6.1  Fingerstick  Risks ............................................................................................................... 28  89 
5.6.2  Subcutaneous Catheter Risks (CGM) ............................................................................... 28  90 
5.6.3  Risk of Hypoglycemia ...................................................................................................... 28  91 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 3 
 5.6.4  Risk of Hyperglycemia ..................................................................................................... 29  92 
5.6.5  Risk of Device Reus e ........................................................................................................ 29  93 
5.6.6  Questionnaire .................................................................................................................... 29  94 
5.6.7  Other Risks ....................................................................................................................... 29  95 
5.7 Risk Assessment  ............................................................................................................... 30  96 
5.8 Study Stoppi[INVESTIGATOR_2121]  .................................................................................................... 30  97 
5.8.1  Criteria for Individual Subjects  ......................................................................................... 30  98 
5.8.2  Criteria for Suspending/Stoppi[INVESTIGATOR_3396] .............................................................. 30  99 
CHAPTER 6:  MISCELLANEOUS CONSIDERATIONS  ....................................................... [ADDRESS_155915] Withdrawal  ........................................................................................................... 31  103 
6.4 Confidentiality  .................................................................................................................. 31  104 
CHAP TER 7:  STATISTICAL CONSIDERATIONS  ............................................................... 31  105 
CHAPTER 8:  DATA COLLECTION AND MONITORING .................................................. 32  106 
8.1 Case Report Forms and Device Data  ................................................................................ 32  107 
8.2 Document Storage and Retention ..................................................................................... 32  108 
BIBLIOGRAPHY  .......................................................................................................................... 33  109 
  110 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 4 
 TABLE OF ACRONYMS  111 
 112 
 113 
  114 Acronym  Abbreviation For  
AP Artificial Pancreas  
BG Blood Glucose  
BT/BTLE  Bluetooth , Bluetooth low energy  
CRF  Case Report Form  
CGM  Continuous Glucose Monitoring  
CLC  Closed -Loop Control  
CSII  Continuous Subcutaneous Insulin Injection  
CTR  Control -to-Range  
DiAs  Diabetes Assistant  
DKA  Diabetic Ketoacidosis  
EC European Commission  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HbA1c  Hemoglobin A1c  
ID Identification  
iDCL  International Diabetes Closed Loop  
IDE Investigational Device Exemption  
IOB Insulin -on-Board  
IQR Interquartile Range  
JDRF  Juvenile Diabetes Research Foundation  
NIH National Institutes of Health  
POC  Point -of-Care  
QA Quality Assurance  
QC Quality Control  
RBM  Risk-Based Monitoring  
SAP Sensor -Augmented Pump  
SD Standard Deviation  
TDD  Total Daily Dose  
UI User Interface  
UVA  University of Virginia  
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 5 
 CHAPTER 1:  INTRODUCTION [ADDRESS_155916]- generation closed -loop control 118 
(CLC) system retaining the same control algorithm that was initially tested by [CONTACT_137348]’s DiAs system 119 
and then implemented in the inControl system. DiAs is described  in 13 IDEs (see IDEs [ADDRESS_155917] below) and inControl is described in IDEs G160097, G160181, G150240, G140169/S010. 121 
For complete algorithmic and clinical background, we refer to these IDEs and to a number of 122 
scientific publications that describe glycemic control outcomes and clinical impressions from the 123 
use of these systems (see list of 25 peer -reviewed papers and scientific presentations under 124 
Bibliography). Overall, this control algorithm has been implemented in two mobile platforms (DiAs 125 
and inControl) and has been tested in [ADDRESS_155918] this progress: 130 
1. IDE #G110095: Feasibility study of closed loop control in type 1 diabetes using heart rate monitoring 131 
as an exercise marker, approved 10/08/2011; 132 
2. IDE #G120032: Early feasibility (pi[INVESTIGATOR_2268]) study of outpatient control- to-range; 3/2/2012; 133 
3. IDE #G120210: Early feasibility study 2 of outpatient control- to-range; 10/12/2012; 134 
4. IDE #G130118: DiAs control- to-range nocturnal closed-loop camp study; 6/19/2013;  135 
5. IDE #G130121: Optimizing closed-loop control of type 1 diabetes mellitus in adolescents; 6/19/2013; 136 
6. IDE# G130142:  Closed loop control in adolescents using heart rate as exercise indicator; 7/16/13;  137 
7. IDE #G130143: Early feasibility study of adaptive advisory/automated (AAA) control of type 1 138 
diabetes; 7/19/2013; 139 
8. IDE #G140066:  Full day and night closed-loop with DiAs platform; 5/9/14. 140 
9. IDE #G140068: Unified Safety System (USS) Virginia Closed Loop versus sensor augmented pump 141 
therapy overnight in type 1 diabetes; 5/14/2014; 142 
10. IDE #G140089: Outpatient control -to-range: Safety and efficacy with day -and-night in-home use; 143 
6/6/2014; 144 
11. IDE #G140169: Unified Safety System (USS) Virg inia Closed -Loop versus Sensor Augmented Pump 145 
(SAP) therapy for hypoglycemia reduction in type 1 diabetes; 10/3/2014. 146 
12. IDE #G150221: Reducing risks and improving glucose control during extended exercise in youth with 147 
T1DM: The AP Ski Camp; 11/09/2015;  148 
13. IDE #G150240: Project Nightlight: Efficacy and system acceptance of dinner/night vs. 24 hr closed 149 
loop control; 11/12/2015; 150 
14. IDE #G160047: Closed-loop in young children 5-8 years old using DiAs platform; 03/29/2016;  151 
15. IDE #G160097: Clinical Acceptance of the Art ificial Pancreas: the International Diabetes Closed - 152 
Loop (iDCL) Trial/Research Site Training Protocol; 06/03/16. 153 
16. IDE#G160181: PROTOCOL 1 for “Clinical Acceptance of the Artificial Pancreas: The International 154 
Diabetes Closed Loop (iDCL) Trial; 09/21/[ADDRESS_155919] inControl implemented on t:slim X2. Based on the 158 
input provided by [CONTACT_137349], we defined a series of three studies leading to a future pi[INVESTIGATOR_137342] 159 
this system. The flowchart of these studies is included in Figure 1:  160 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 6 
  161 
Figure 1:  Sequence of planned studies leading to a future pi[INVESTIGATOR_137343] X2 insulin [ADDRESS_155920] a separate IDE submission  163 
 164 
Closed -Loop Control System 165 
The Closed -Loop Control System contained in t -slim X2 with Control- IQ Technology is described 166 
in Master File MAF -2032/A003. Control- IQ Technology is derived from inControl previously 167 
described in I DE# G160097,G160181, G150240 and G140169/S010. The CLC  is an “artificial 168 
pancreas” (AP) application that uses advanced closed loop control algorithms to automatically 169 
manage blood glucose levels for people with Type 1 Diabetes . The system modulates insulin to keep 170 
blood glucose in a targeted range. The system components include the t:slim X2 with Control- IQ 171 
Technology and the Dexcom CGM G6 ( Figure 2). 172 
Figure 2: t:slim X2 with Control -IQ and Dexcom G6 system 173 

 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 7 
 1.2. Synopsis of Study  Protocol  174 
1.2.1. Study Objective  175 
The objective of the study is for clinical staff to gain experience using the proposed artificial 176 
pancreas system named t:slim X2 with Control-IQ Technology and assess usability in a supervised 177 
setting prior to initiating home use  in a Training protocol (IDE submission pending ).  178 
  179 
1.2.2. Major Eligibility Criteria  180 
• Clinical diagnosis of type [ADDRESS_155921] 1 year  181 
• Use of an insulin infusion pump for at least 6 months  182 
• Age 18 to <75 years old  183 
• Hemoglobin A1c <10.5%  184 
• Currently using no insulins other than one of the following rapid- actin g insulins at the time 185 
of enrollment: insulin lispro (Humalog), insulin aspart (Novolog), or insulin glulisine 186 
(Api[INVESTIGATOR_27976]). Willingness to switch to lispro (Humalog) or aspart (Novolog) if using glulisine 187 
(Api[INVESTIGATOR_27976]).  188 
• No more than one epi[INVESTIGATOR_66676] (DKA) or severe hypoglycemia 189 
involving a seizure of loss of consciousness in the 6 months prior to enrollment  190 
• Total daily insulin dose at least 10 units/day and ≤ 100 U/day  [ADDRESS_155922] approximately 36-48 hours in a supervised setting using the study 198 
CGM and study pump as detailed in Figure 3 below .  199 
Figure 3: Enrollment Flow Diagram 200 
 
 Visit 1: Screening / Enrollment Visit  
•Eligibility assessment and informed consent  
•HbA1c from local la b or POC device  
Visit 2: 36- 48 hour Supervised Study using 
t:slim X2 with Control -IQ 
Visit 3:  Study Staff Contact [CONTACT_137350]   
•Assessment within 36 hours after Visit 2  
 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 8 
 1.2.5. Outcomes  201 
The primary outcome is a qualitative assessment of the system’s suitability for use in a n in-home [ADDRESS_155923] 206 
as described in CHAPTER 7 :  STATISTICAL CONSIDERATIONS . [ADDRESS_155924] the s tudy.  218 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 18 
 CHAPTER 2:  VISIT 1: SUBJECT  SCREENING AND ENROLLMENT  [ADDRESS_155925] meet the following criteria:  228 
1) Clinical diagnosis, based on investigator assessment, of type [ADDRESS_155926] 1 year  230 
2) Use of an insulin pump for at least 6 months with established parameters for basal rate(s), 231 
carbohydrate ratio(s) and insulin sensitivity factor(s) for at least 3 months. 232 
3) Age 18.0 to <75.0 years 233 
4) Hemoglobin A1c <10.5% 234 
5) For females, not currently known to be pregnant [ADDRESS_155927] will be required for 237 
all premenopausal women who are not s urgically sterile.  Subjects who become pregnant will 238 
be discontinued from the study. Also, subjects who during the study develop and express the 239 
intention to become pregnant within the timespan of the study will be discontinued.  240 
6) Willingness to suspend use of any personal CGM for the duration of the clinical trial once the 241 
study CGM is in use  242 
7) Investigator has confidence that the subject can successfully operate all study devices and is 243 
capable of adhering to the protocol 244 
8) Currently using no insulins other than one of the following rapid- acting insulins at the time 245 
of enrollment: insulin lispro (Humalog), insulin aspart (Novolog), or insulin glulisine 246 
(Api[INVESTIGATOR_27976]). Willingness to switch to lispro (Humalog) or aspart (Novolog) if using glulisine 247 
(Api[INVESTIGATOR_27976]).  248 
9) Total dai ly insulin dose (TDD) at least  10 U/day and ≤100 U/day 249 
10) Weight at least 25 kg and not greater than 140 kg 250 
 251 
2.2.2. Exclusion  252 
The presence of any of the following is an exclusion for the study: 253 
1) More than one epi[INVESTIGATOR_66676] (DKA) in the 6 months prior to enrollment 254 
2) More than one epi[INVESTIGATOR_137344] 255 
the 6 months prior to enrollment  256 
3) Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists, 257 
Symlin, DPP -4 inhibitors, S GLT -2 inhibitors, biguanides, sulfonylureas and naturaceuticals).  258 
4) Hemophilia or any other bleeding disorder 259 
5) A condition, which in the opi[INVESTIGATOR_66678], would put the subject  or 260 
study at risk  261 
6) Participation in another pharmaceutical or device trial at the time of enrollment or during the 262 
study 263 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 19 
 7) Employed by, or having immediate family members employed by [CONTACT_137351], [ADDRESS_155928] of employment 265 
who is also directly involved in conducting the clinical trial (as a study investigator, 266 
coordinator, etc.); or having a first-degree relative who is directly involved in conducting the [ADDRESS_155929]’s routine care. [ADDRESS_155930] exclusion will be at the discretion 282 
of the investigator based on study inclusion/exclusion criteria.    [ADDRESS_155931] physical exam (including vital signs , height and weight measurements ) will be 289 
performed by [CONTACT_3437] (a physician, fellow, nurse practitioner or a 290 
physician assistant).   291 
 292 The following procedu res will be performed/data collected/eligibility criteria checked and 293 
documented:  294 
• Subject fully informed about the study and informed consent form signed according to IRB 295 
requirements  296 
• Inclusion and exclusion criteria assessed  297 
• Demographics (date of birth, gender, race and ethnicity)  298 
• Contact [CONTACT_3031]  299 
• Diabetic history  300 
• Medical history  301 
• Substance use history (drinking, smoking, and drug habits) 302 
• Concomitant medications  303 
• Physical examination to include: 304 
o Weight, height 305 
o Vital signs including measurement of  temperature,  blood pressure and pulse 306 
• HbA1c level measured using the DCA2000 or comparable point of care device or local lab 307 
(used to assess eligibility)  [ADDRESS_155932] be made within two weeks prior to enrollment 309 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 20 
 o Measurement performed as part of usual  clinical care prior to obtaining informed 310 
consent for participation in the trial may be used  311 
• Urine or serum pregnancy test for all premenopausal women who are not surgically sterile [ADDRESS_155933] approximately 1 -2 hours.  314 
  315 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 21 
 CHAPTER 3:  VISIT 2: 36-48- HOUR SUPERVISED STUDY [ADDRESS_155934] 326 
Charlottesville, VA  [ZIP_CODE]                                      327 
 328 
3.2. Procedures upon Arrival to the Study Site  329 
The subjects will be assessed with vital signs. Subjects will not be allowed to initiate the study in 330 
the presence of fever or other significant illness within 24-hours of admission. A fingerstick BG 331 
and fingerstic k ketone measurement will be performed and Glycemic Guidelines followed 332 
(Appendix A-11). Female subjects of childbearing potential will perform a urine pregnancy test. [ADDRESS_155935] and the appropriate medical care. 335 
 336 
 337 3.3. Study Device Initiation and Training  338 
Subjects will receive study system  training by a qualified trainer . The study system includes the 339 
Tandem t:slim X2 with Control-IQ technolog y and associated Dexcom G6 CGM.  340 
 341 
Study Pump and CGM training will include: 342 
• The subject will be fully instructed on the study insulin pump. A qualified staff [ADDRESS_155936] and correction 345 
boluses. Additional topi[INVESTIGATOR_137345]: infusion site initiation, 346 
cartridge/priming procedures, setting up the pump, charging the pump, navigation 347 
through menus, bolus procedures including stoppi[INVESTIGATOR_007] a bolus, etc. 348 
• The study team will assist the subject in study pump infusion site initiation and will [ADDRESS_155937]’s usual basal rates and pump parameters. The subject’s personal pump will be 351 
removed. 352 
• The subject will be encouraged to review the literature provided with the pump and 353 
infusion sets after the training is completed.  354 
• The subject will learn how to calibrate the CGM unit during the study . 355 
• The su bject will learn how to access the CGM trace via the t:slim X2 with Control- IQ 356 
user interface. 357 
• Subjects will be asked to perform fingerstick blood glucose measurements in 358 
accordance with the labeling of the study CGM device.  359 
 360 
Pump training specific to the  Control-IQ Technology functions will include: 361 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 22 
 • How to turn on and off Control-IQ technology. 362 
• How to understand when Control- IQ is increasing or decreasing basal rates.  363 
• How to administer a meal or correction bolus on the t:slim X2 with Control- IQ system  364 
• What to do when exercising while using the system. 365 
• How to enable the sleep function and set the sleep schedule. 366 
• The subject will be assessed for understanding of the system interface and how to react to 367 
safety/alert messages.  368 
• The subject will be given a User Guide as a reference. 369 
 370 
Blood glucose testing 371 
• All study blood glucose meters will be QC tested with at least two different 372 
concentrations of control solution if available at the start of the admission.  A tested 373 
meter will not be used in a study if it doe s not read within the target range at each 374 
concentration per manufacturer labeling.   375 
• Subjects will be reminded to use the study blood glucose meter for all fingerstick BGs 376 
during the study.   377 
 378 
Blood ketone testing 379 
• All study blood ketone meters will be QC tested with at least two different concentrations 380 
of control solution if available at the start of the admission.  A tested meter will not be 381 
used in a study if it does not read within the target range at each concentration per 382 
manufacturer labeling  383 
• Subjects will be instructed to perform blood ketone testing as described in Appendix A- [ADDRESS_155938] restaurant meals and offered any snacks per their usual routine. Subjects 389 
will participate in supervised exercise per their usual routine (e.g. walking 30-45 minutes). 390 
Subjects will simulate an infusion site change and a sensor change during the study. 391 
 392 
3.5. Procedures for Monitoring  393 
Subjects will be asked to perform fingersticks prior to meals and any user- initiated corre ction 394 
boluses. Subjects will be asked to perform a fingerstick in the event of a Control- IQ Low Alert or 395 
Control- IQ High Alert. Glycemic Guidelines (Appendix A-11) will be followed during the [ADDRESS_155939] every 2 hours 402 
during the day and every 3 hours at night. 403 
 404 Subjects will be instructed to notify staff of any alerts/alarms received .  [ADDRESS_155940] one of whom 408 
will be  clinical staff ( e.g. nurse, physician, nurse practitioner). There will be a physician 409 
available either on -site or nearby [CONTACT_78150] -site at all times. Glucagon for the emergency treatment of 410 
hypoglycemia will be available on -site. 411 
 412 
3.7 Visit 3: Follow- up Visit  413 
Subjects will be contact[CONTACT_137352] 36 hours of discharge to assess for any adverse 414 
events, significant hypoglycemia or significant hyperglycemia. 415 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 24 
 CHAPTER 4:  SAFETY MEASURES  416 
 417 
4.1 Safety Measures  418 
 419 4.1.1 CGM Calibration  420 
Throughout the study, subjects will be instructed to calibrate the study CGM in accordance with 421 
manufacturer labelling.  422 
 423 4.1.2 Insulin Dosing  424 
 When Control-IQ is turned on, subjects are expected to input carbohydrates in order to bolus for a 425 
meal and may also administer correction boluses if desired. In case of a system crash or any 426 
interru ption of communication between t:slim X2 with Control- IQ and the CGM , the pump will 427 
revert to open-loop basal delivery within a short period of time. The system has a Max Insulin 428 
Alert that is triggered when the 2 -hour insulin delivery has administered 50% of the Total Daily 429 
Insulin (TDI). No further insulin will be delivered until this condition is no longer present.   430 
 431 4.1.3 Hypoglycemia Safety Protocol  432 
All subjects will be required to set the CGM hypoglycemia threshold alarm to a value no less than 433 
60 mg/dl. 434 
 435 
The t:slim X2 with Control- IQ system will issue a hypoglycemia alarm (Control- IQ Low Alert)  436 
if the CGM is <70 mg/dL or when the system predicts BG <70 mg/dL within the next 15- [ADDRESS_155941] receives a hypoglycemia alarm from t:slim X2 with Control- IQ, a message 440 
appears on the UI that is accompanied by [CONTACT_137353]/or sound if n ot [ADDRESS_155942] blood sugar and treat with carbs.   443 
 444 
4.1.4 Hyperglycemia Safety Protocol  445 
Subjects will be required to set the CGM hyperglycemia threshold alarm to a value no greater than 446 
300 mg/dl. 447 
 448 
The t:slim X2 with Control- IQ system will issue a predictive hyperglycemia alarm (Control- 449 
IQ High Alert)  if the system detects prolonged resistance to insulin treatment and the BG is 450 
estimated to be above 200 mg/dL. [ADDRESS_155943] receives a hyperglycemia alarm from t:slim X2 with Control- IQ, a message 453 
appears on the UI that is accompanied by [CONTACT_137354]/or sound if not [ADDRESS_155944]’s CGM reading is ≥300 mg/dL for over 1 hour, or ≥400 mg/dL at any point, the 458 
following steps will be taken : 459 
• Perform a blood glucose meter check. 460 
• If the blood glucose is >300 mg/dL, check for blood ketones with the study ketone meter. 461 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 25 
 • If the ketone level is >0.6 mmol/L, study s taff will assist subject in taking correction 462 
insulin or changing the pump infusion set.   463 
• If a subject administer s correction insulin via insulin syringe, subjects will be instructed to 464 
turn Control- IQ off for a few hours and can be restarted per study physician evaluation 465 
within 4 hours. 466 
 467 
4.1.5 Study Data  Monitoring  468 
Study staff will download the t:slim X2 at the completion of the admission. These data will be [ADDRESS_155945] insulin . If the CGM  is not connected, the 475 
system will revert to usual function of the pump and deliver insulin with the insulin dosing 476 
parameters programmed in the system for that individual. Resumption of Closed- Loop will resume 477 
automatically once CGM signal is available again.  478 
 479 4.1.7 Control- IQ Connection Failure  480 
If the study system is unable to activate Control- IQ for any reason, the pump will automatically 481 
revert to preprogrammed basal insulin delivery without any need for instruction from the user. 482 
 483 4.1.8 Study System Failure  484 
If the t:slim X2 detects a system error that does not allow the pump to operate, the  Malfunction [ADDRESS_155946] Tandem Technical Sup port and the 486 
study team.  487 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 26 
 CHAPTER 5:  ADVERSE EVENTS, DEVICE ISSUES, POTENTIAL RISKS, AND [ADDRESS_155947] that 492 
is study - or device- related , including severe hypoglycemia  as defined below and severe 493 
hyperglycemia/diabetic ketoacidosis (DKA) as defined below.  Skin reactions from sensor 494 
placement are only reportable if severe and/or required treatment.  495 
 496 
Hypoglycemic events are recorded as Adverse Events (severe hypoglycemic  event) if the event [ADDRESS_155948]  was impaired cognitively to the point that he/she was unable to treat himself/herself, was 500 
unable to verbalize his/ her needs, was incoherent, disoriented, and/or combative, or experienced 501 
seizure or coma. These epi[INVESTIGATOR_137346] 502 
seizure or coma.   If plasma glucose measurements are not available during such an event, 503 
neurological recovery attributable to the restoration of plasma glucose to normal is considered 504 
sufficient evidence that the event was induced by a low plasma glucose concent ration. 505 
 506 Hyperglycemic events are recorded as Adverse Events (severe hyperglycemic event) if the event 507 
involved DKA, as defined by [CONTACT_3467] (DCCT) and 508 
described below , or in the absence of DKA if evaluation or treatment was obtained at a health care 509 
provider facility  for an acute event involving hyperglycemia or ketosis.  510 
 511 Hyperglycemic events are classified as DKA if the following are present:  512 
• Symptoms such as polyuria, polydipsia, nausea, or vomiting;  513 
• Serum ketones >1 .5 mmol/L or large/moderate urine ketones;  514 
• Either arterial blood pH <7.30 or venous pH <7.24 or serum bicarbonate <15; and 515 
• Treatment provided in a health care facility     [ADDRESS_155949] been caused by 529 
the study intervention. 530 
 531 To ensure consistency of adverse event causality assessments, investigators should apply the 532 
following general guideline when determining whether an adverse event is related:  [ADDRESS_155950]’s clinical state, 537 
intercurrent illness, or concomitant therapi[INVESTIGATOR_014]; and/or the adverse event follows a known pattern of 538 
response to the study intervention; and/or the adverse event abates or resolves upon [ADDRESS_155951] udy intervention (e.g., 544 
preexisting medical condition, underlying disease, intercurrent illness, or concomitant 545 
medication); and/or the adverse event has no plausible temporal relationship to study intervention.    546 
 547 
The intensity of adverse events will be rated on a three-point scale: (1) mild, (2) moderate, or (3) 548 
severe.  It is emphasized that the term severe is a measure of intensity: thus, a severe adverse event [ADDRESS_155952]’s discontinuation or completion of the study [ADDRESS_155953] occurrence that:  560 
• Results in death. 561 
• Is life -threatening; (a non- life-threatening event which, had it been more severe, might [ADDRESS_155954] become life-threatening, is not necessarily considered a serious adverse event). 563 
• Requires inpatient hospi[INVESTIGATOR_1081]. 564 
• Results in persistent or significant disability/inca pacity or substantial disruption of the [ADDRESS_155955] normal life functions (sight threatening). 566 
• Is a congenital anomaly or birth defect.  567 
• Is considered a significant medical event by [CONTACT_13656] 568 
(e.g., may jeopardize the subject  or may require medical/surgical intervention to prevent 569 
one of the outcomes listed above). [ADDRESS_155956], problem, or death was not previously identified in nature, severity, or degree of incidence 574 
in the investigational plan or application (including a supplementary plan or application), or any 575 
other unanticipated serious problem associated with a device that relates to the rights, safety, or 576 
welfare of subjects (21 CFR 812.3(s)).  577 
 578 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 28 
 Serious or unexpected related adverse events will be reported to the local IRB’s online adverse [ADDRESS_155957].   583 
 584 
5.4 Device Issues  585 
Device malfunctions (failure of device to perform as intended) will be reported to the 586 
manufacturer , irrespective of whether associated with an adverse event.  However, CGM sensors 587 
lasting fewer  than 10 days and tape adherence issues will not be reported unless associated with an 588 
adverse event. Additionally, t:slim X2 with Control- IQ component disconnections will not be 589 
reported unless associated with an adverse event. 590 
 591 5.5 Medical Monitor  592 
The Medical Monitor will be informed of all serious adverse events and any unanticipated adverse 593 
device events that occur du ring the study.   594 
 595 5.6 Potential Risks and Side Effects  596 
Loss of confidentiality is a potential risk; however, data are handled to minimize this risk.  [ADDRESS_155958] for several w eeks.  The 608 
risk of local infection is less than 1 in 1000.  This should not be a significant contributor to risks in 609 
this study as fingersticks are part of the usual care for people with diabetes.  610 
 611 
5.6.2 Subcutaneous Catheter Risks (CGM)  612 
Subjects using the CGM will be at low risk for developi[INVESTIGATOR_007] a local skin infection at the site of the 613 
sensor needle placement.  If a catheter is left under the skin for more than 24 hours it is possible to 614 
get an infection where it goes into the skin, with swelling, redness and pain.  There may be 615 
bleeding where the catheter is put in and bleeding under the skin causes a bruise (1 in 10 risk).   [ADDRESS_155959] should be further instructed to notify the study coordinator immediately if this 620 
occurs.  621 
 622 
5.6.3 Risk of Hypoglycemia  623 
As with any person having type 1 diabetes and using insulin, there is always a risk of having a low 624 
blood sugar (hypoglycemia).  The frequency of hypoglycemia should be no more and possibly less [ADDRESS_155960] as at home, there is the possibility of fainting or seizures 627 
(convulsions) and that for a few days the subject may not be as aware of symptoms of 628 
hypoglycemia .  A CGM functioning poorly and significantly over- reading glucose values could 629 
lead to inappropriate insulin delivery.     630 
 631 
5.6.4 Risk of Hyperglycemia  632 
Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for an 633 
extended period or if the pump or infusion set is not working properly.  A CGM functioning 634 
poorly and significantly under-reading glucose values could lead to inappropriate suspension of 635 
insulin delivery.     636 
 637 5.6.5 Risk of Device Reuse  638 
The study CGM system is intended for single use only. The sensor (the component of the system 639 
that enters t he skin) will be single use only. The transmitter and receiver may be reused during the [ADDRESS_155961] approved these devices for single 643 
use and that by [CONTACT_28040], bloodborne pathogens (i.e. Hepatitis B) may 644 
be spread through the use of multiple users.  645 
 646 
The study insulin pump is intended for single -patient use. During the study, this device may be 647 
reused after cleaning adhering to a hospi[INVESTIGATOR_307] -approved cleaning procedure. All infusion set 648 
equipment will be single patient use only (infusion set insertion kits, tubing, cartridges etc.)  649 
Subjects will be informed that FDA or relevant national authorities typi[INVESTIGATOR_137347] 650 
pump devices for single use and that by [CONTACT_28040], bloodborne 651 
pathogens (i.e. Hepatitis B) may be spread through the use of multiple users. 652 
 653 The study blood glucose meter and blood ketone meter are labeled for single-patient use. During 654 
the study, only one person can use each device as there are rare risks that bloodborne pathogens 655 
(i.e. Hepatitis B) may be spread through the use of multiple users.  656 
 657 
5.6.6 Questionnaire  658 
As part of the study, subjects will complete a Technology Acceptance Questionnaire which 659 
includes questions about their private attitudes, feelings and behavior related to t:slim X2 with [ADDRESS_155962] been 662 
uncommon. 663 
 664 
5.6.7 Other Risks  665 
Some subjects may develop skin irritation or allergic reactions to the adhesives used to secure the 666 
CGM, or to secure the insulin infusion sets for the continuous subcutaneous insulin infusion.  If 667 
these reactions occur, different adhesives or “under- tapin g” (such as with IV 3000, Tegaderm, 668 
etc.) will be tried, sites will be rotated frequently, and a mild topi[INVESTIGATOR_91101] 669 
medication may be required. 670 
 671 
Whenever the skin is broken there is the possibility of an infection.  The CGM and pump infusion 672 
sites are inserted under the skin.  It is possible that any part that is inserted under the skin may 673 
cause an infection.  These occur very infrequently, but, if an infection was to occur, oral and/or [ADDRESS_155963] s will be carefully instructed about proper 676 
use of the sensor. 677 
 678 
Data downloaded from the CGM, pump, and the home glucose and ketone meter will be coll ected 679 
for the study as measures of diabetes self -management behaviors.  Some people may be 680 
uncomfortable with the researchers' having such detailed information about their daily diabetes 681 
habits. 682 
 683 
5.7 Risk Assessment  684 
Based on the facts that (1) adults and adole scents with diabetes experience mild hypoglycemia and 685 
hyperglycemia frequently as a consequence of the disease and its management, (2) the study 686 
intervention involves periodic automated insulin dosing that may increase the likelihood of 687 
hypoglycemia, and periodic automated attenuation of insulin delivery that may increase the 688 
likelihood of hyperglycemia, (3) mitigations are in place, and have been tested in prior studies 689 
using similar  investigational device system in the home setting, that limit the likelih ood of 690 
excessive insulin dosing or prolonged withdrawal of insulin, and (4) rapid reversal of [ADDRESS_155964] are as follows: [ADDRESS_155965], unless the 701 
problem can be clearly identified and the system definitively repaired  702 
2. Severe hypoglycemia or hyperglycemia/DKA (not associated with infusion set failure) as [ADDRESS_155966] pregnancy 706 
 707 5.8.2 Criteria for Suspending/Stoppi[INVESTIGATOR_3396]  708 
In case of a system malfunction resulting in a severe hypoglycemia or severe hyperglycemia event 709 
(as defined in Section 5.1) that is thought to be device- related (either due to excess insulin 710 
administration or suspension due to system malfunction) and occurs more than one time, the 711 
overall study will be suspended while the problem is diagnosed.  In addition, the study could be 712 
suspended if the manufacturer of any constituent study device requires stoppage of device use for 713 
safety reasons (e.g. product recall). The study may resume if the underlying problem can be [ADDRESS_155967] suspension or outright stoppage of the study if deemed necessary based on the totality of 720 
safety data available.  721 
 722 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 31 
 CHAPTER 6:  MISCELLANEOUS CONSIDERATIONS  [ADDRESS_155968] Compensation 735 
Subjects will be paid $ 150 for completing the Pi[INVESTIGATOR_16116] .   736 
• Visit #2 (Supervised Hotel Study):  $125 737 
• Visit #3 (Follow- Up Visit ) - $[ADDRESS_155969] may withdraw at any time.  For subjects who 741 
withdraw, their data will be used up until the time of withdrawal.  742 
 743 
6.4 Confidentiality  744 
For security and confidentiality purposes, subjects will be assigned an identifier that will be used 745 
instead of their name.  De-identified data will be shared with  the Jaeb  Center for Health Research 746 
in Tampa, FL.  De-identified data will also be provided to Tandem for system evaluation 747 
purposes. 748 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 31 
 
 CHAPTER 7 :  STATISTICAL CONSIDERATIONS  1 
 2 The intent of this protocol is to introduce the t:slim X2 with Control- IQ system prior to proceeding [ADDRESS_155970], and tabulate any t:slim X2 with Control- IQ errors that would inform us 7 
whether system fixe s would be needed prior to its deployment in the home trial .  We will tabulate 8 
technical performance metrics including:  9 
• % time in closed -loop and any other relevant operational modes 10 
• % time CGM data available to the controller  11 
• Rate of relevant failure events and alarms per [ADDRESS_155971] based on CGM data, including: 15 
• mean glucose  16 
• percentage of readings in the target range of 70 -180 and 70-140 mg/dl  17 
• glucose variability measured with the standard deviation and coefficient of variation  18 
• percentage of readings <70, 60, and 54 mg/dl  19 
• nadir  20 
• AUC glucose <70, 60, and 54 mg/dl  21 
• low blood glucose index 22 
• percentage of readings >180, 250, and 300 mg/dl  23 
• AUC glucose >180 mg/dl  24 
• high blood glucose index  25 
 26 
The technical performance, errors, and glycemic analyses will be split by [CONTACT_137355]: daytime 27 
vs. nighttime  28 
 29 
  30 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 32 
 
 CHAPTER 8:  DATA COLLECTION AND MONITORING  31 
 32 
8.1 Case Report Forms and Device Data  33 
The main study data are collected through a combination of electronic case report forms (CRFs) 34 
and electronic device data files obtained from the study software and individual hardware 35 
components.  These electronic device files and electronic CRFs are considered the primary source 36 
documentation. 37 
 38 8.2 Document Storage and Retention  39 
• The Investigator will retain all records and documents pertaining to this study. They will 40 
be available for inspection by [CONTACT_116693]. In addition, the 41 
Investigator will retain the source documents from which the information entered on the 42 
CRFs was derived. These records are to be retained in a secure storage facility maintained 43 
by [CONTACT_137356] 3 years (or longer/shorter if local laws require) after 44 
approval of the above-listed study devices or termination of the study, whichever is longer. 45 
The investigator should take measures to prevent accidental or early destruction of the 46 
clinical study related materials.   47 
 48 
 49   50 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 33 
 
 BIBLIOGRAPHY  51 
 52 
(1) Kovatchev, B.P., Breton, M.D., Keith- Hynes, P.T., Patek, S.D. The Diabetes Assistant (DiAs) – 53 
Unified platform for monitoring and control of blood glucose levels in diabetic patients ; [ADDRESS_155972]/US12/[ZIP_CODE], 2012. 55 
(2) Keith -Hynes, P., Guerlain, S., Mize, L.B., Hughes- Karvetski, C., Khan, M., McElwee-Malloy, M. & 56 
Kovatchev, B.P. DiAs user interface: A patient- centric interface for mobile artificial pancreas systems. 57 
J Diabetes Sci Technol , 7, 1416–1426 (2013). PMID: 24351168 58 
(3) Place, J., Robert, A., Ben Brahim, N., Keith-Hynes, P., Farret, A., Pelletier, M.J., Buckingham, B., 59 
Breton, M., Kovatchev, B.P. & Renard, E. DiAs web monitoring: A real- time remote monitoring 60 
system designed for artificial pan creas outpatient trials. J Diabetes Sci Technol , 7, 1427–1435. (2013). 61 
PMID: 24351169 62 
(4) Keith -Hynes, P., Mize, B., Robert, A., Place, J. The Diabetes Assistant: A smartphone- based system 63 
for real -time control of blood glucose. Electronics 2014, 3, 609-623; doi:10.3390/electronics3040609 64 
(5) Kovatchev, B.P., Renard, E., Cobelli, C., Zisser, H., Keith-Hynes, P., Anderson, S.M. Brown, S.A. [ADDRESS_155973], J., Bruttomesso, D., Del Favero, S., 66 
Visentin, R., Filippi,  A., Scotton, R., Avogaro, A. & Doyle III, F.J. Feasibility of outpatient fully 67 
integrated closed -loop control: First studies of wearable artificial pancreas. Diabetes Care , 36, 1851- 68 
1858 doi: 10.2337/dc12-1965 (2013). PMID: 23801798, PMCID: PMC3687268  69 
(6) Kovatchev, B.P., Renard, E., Cobelli, C., Zisser, H., Keith-Hynes, P., Anderson, S.M., Brown, S.A., [ADDRESS_155974], J., Bruttomesso, D., Del Favero, S., 71 
Boscari, F., Galasso, S., Avogaro, A., Magni, L., Di Palma, F., Toffanin, C., Messori, M., Dassay, E., 72 
Doyle, F. III. Safety of outpatient closed- loop control: First randomized crossover trials of a wearable 73 
artificial pancreas. Diabetes Care, 37 , 1789- 1796 doi: 10.2337/dc13-2076 (2014). PMID: 24929429, 74 
PMCID:  PMC4067397 75 
(7) DeSalvo, D., Keith-Hynes, P., Peyser, T., Place, J., Caswell, K., Wilson, D., Harris, B., Clinton, P., 76 
Kovatchev, B.P. , Buckingham, B.A. Remote glucose monitoring in camp setting reduces the risk of 77 
prolonged nocturnal hypoglycemia. Diabetes Te chnol Ther , 16, 1- 7 doi:10.1089/dia.2013.0139 (2013). 78 
PMID: 24168317 79 
(8) Ly, T.T., Breton, M.D., Keith-Hynes, P., De Salvo, D., Clinton, P., Benassi, K., Mize, L.B., [ADDRESS_155975], J., Wilson, D.M., Kovatchev, B.P., Buckingham, B.A. Overnight glucos e 81 
control with an automated, unified safety system in children and adolescents with type 1 diabetes at 82 
diabetes camp.  Diabetes Care , 37, doi: 10.2337/dc14-0147 (2014). PMID: 24879841, PMCID: 83 
PMC4179507 84 
(9) Kropff, J., Del Favero, S., Place, J., Toffanin, C., V isentin, R., Monaro, M., Messori, M., Di Palma, F., [ADDRESS_155976], E., Magni, L., for the AP@home 87 
consortium. 2 month evening and night closed-loop glucose control in patients with Type 1 Diabetes 88 
under free -living conditions: A randomised crossover trial. Lancet Diabetes Endocrinol, 3(12) :939-47 89 
dx.doi.org/10.1016/S2213-8587(15)[ZIP_CODE]-6 (2015).  90 
(10) Renard, E et al.  Reduction of hyper - and hypoglycemia during two months with a wearable [ADDRESS_155977] in patients with type 1 diabetes. 2015-A-3083- Diabetes. 92 
American Diabetes Association 75th Scientific Sessions , [LOCATION_011], MA, poster 940- P. 93 
(11) Anderson, S et al. First New Year’s Night on closed-loop control (CLC) at home: Case reports 94 
from a multi -center international trial of long-term 24/7 CLC. 2015-A-4763- Diabetes. American 95 
Diabetes Association 75th Scientific Sessions, [LOCATION_011], MA, presentation 223–OR.  96 
(12) Kovatchev BP. JDRF Multi -Center 6 -Month Trial of 24/7 Closed-Loop Control. Advanced 97 
Technologies and Treatments for Diabetes (ATTD) , Plenary Session, Milan, Italy, 2016. 98 
(13) Kovatchev, B.P. Closed-loop control modalities in type 1 diabetes: Efficacy and system 99 
acceptance.  Advanced Technologies and Treatments for Diabetes (ATTD) , Paris, [LOCATION_009], 2015. 100 
 
iDCL Protocol 3_PI[INVESTIGATOR_137341]_V1.0.docx  Page 34 
 
 (14) Del Favero S. A multicenter randomized cross- over Italian pediatric summer camp: AP vs SAP in 101 
5-8 year old children. Advanced Technologies and Treatments for Diabetes (ATTD) , Plenary Session, 102 
Milan, Italy, 2016. 103 
(15) Cherñavvsky, D. et al. Closed-loop control during extended winter-sport exercise in youth with 104 
T1DM: Results from the first AP ski camp. ATTD Data Club Session, Milan, (2016).  105 
(16) Chernavvsky, D.R., D eBoer, M.D., Keith-Hynes, P., Mize, B., McElwee, M., Demartini, S., 106 
Dunsmore, S.F., Wakeman, C., Kovatchev, B.P., Breton, M.D. Use of an artificial pancreas among 107 
adolescents for a missed snack bolus and an underestimated meal bolus. Pediatric Diabetes, 108 
doi:10.1111/pedi.[ZIP_CODE] (2014). PMID: 25348683 109 
(17) Brown, S.A., Kovatchev, B.P., Breton, M.D., Anderson, S.M., Keith-Hynes, P., Patek, S.D., Jiang, 110 
B., Ben Brahim, N., Vereshchetin, P., Bruttomesso, D., Avogaro, A., Del Favero, S., Boscari, F., 111 
Galasso, S., Visen tin, R., Monaro, M., Cobelli, C. Multinight “bedside” closed-loop control for patients 112 
with type 1 diabetes. Diabetes Technol Ther  17(3), doi:10.1089/dia.2014.0259 (2015). PMID: 113 
25594434, PMCID: PMC4346235 114 
(18) Kovatchev BP, Tamborlane WV, Cefalu WT, Cobelli C. The Artificial Pancreas in 2016: A Digital 115 
Treatment Ecosystem for Diabetes. Diabetes  Care 2016; 39:1123-27. PMID: 27330124 116 
(19) Del Favero S, Boscari F, Messori M, Rabbone I, Bonfanti R, Sabbion A, IaFusco D, Schiaffini R, 117 
Visentin R, Calore R, Moncada YL, Ga lasso S, Galderisi A, Vallone V, Di Palma F, Losiouk E1, 118 
Lanzola G1, Tinti D, Rigamonti A, Marigliano M, Zanfardino A, Rapi[INVESTIGATOR_9384] N, Avogaro A, Chernavvsky 119 
D, Magni L, Cobelli C, Bruttomesso D. Randomized Summer Camp Crossover Trial in 5- to 9- Year - 120 
Old Childre n: Outpatient Wearable Artificial Pancreas Is Feasible and Safe. Diabetes Care.  121 
2016;39:1180-5. PMID: 27208335 122 
(20) Renard E, Farret A, Kropff J, Bruttomesso D, Messori M, Place J, Visentin R, Calore R, Toffanin 123 
C, Di Palma F, Lanzola G, Galasso S, Avogaro A, K eith-Hynes P, Kovatchev BP, Del Favero S., 124 
Cobelli C, Magni L, DeVries HJ. AP@home Consortium. Day and night closed loop glucose control in 125 
patients with type 1 diabetes under free-living conditions: comparison of a single- arm, 1 -month 126 
experience to result s of a previously reported feasibility study of evening and night at home. Diabetes 127 
Care 2016; 39:1151-60. PMID: 27208331 128 
(21) Anderson SM, Raghinaru D, Pi[INVESTIGATOR_45905], Boscari F, Renard E, Buckingham BA, Nimri R, Doyle FJ [ADDRESS_155978] J, Ly TT, Shanmugham S, Phillip M, 131 
Dassau E, Dasanayake IS, Kollman C, Lum JW, Beck RW, and Kovatchev BP. Multinational home use 132 
of closed -loop control is safe and effective. Diabetes Care 2016; 39:1143-1150. PMID: 27208316 133 
(22) DeBoer MD, Cherñavvsky DR, Topchyan K, K ovatchev BP, Francis GL, Breton MD. Heart rate 134 
informed artificial pancreas system enhances glycemic control during exercise in adolescents with 135 
T1D. Pediatr Diabetes . 2016; doi: 10.1111/pedi.[ZIP_CODE]. PMID: 27734563 136 
(23) Kovatchev BP, Cheng P, Anderson SM, Pi[INVESTIGATOR_45905], Boscari F, Buckingham BA, Doyle FJ. III, [ADDRESS_155979], Bevier WC, Bradley PK, Bruttomesso D, Del 138 
Favero S, Calore R, Cobelli C, Avogaro A, Ly TT, Shanmugham S, Dassau E, Kollman C, Lum JW, 139 
Beck RW, for the Control to Range Study Group. Feasibility of Long- Term Closed -Loop Control: A 140 
Multicenter 6 -Month Trial of 24/7 Automated Insulin Delivery. Diabetes Technol Ther  2017; 19: 18- 141 
24. doi:10.1089/dia.2016.0333. PMID: 27982707 142 
(24) DeBoer MD, Breton MD, Wakeman CA, Schertz EM, E mory EG, Robic JL, Kollar LL, Kovatchev [ADDRESS_155980]. Performance of an Artificial Pancreas System for Young Children with Type 1 144 
Diabetes. Diabetes Technol Ther  2017; 19, DOI: 10.1089/dia.2016.0424. PMID: 28426239 145 
(25) Breton MD, Cherñavvsky DR, Forlenza GP, DeBoer MD, Robic J, Wadwa RP, Messer LH,  146 
Kovatchev BP, Maahs DM. Closed Loop Control During Intense Prolonged Outdoor Exercise in 147 
Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study. Diabetes Care  2017 Aug; 148 
dc170883. https://doi.org/10.2337/dc17-0883 149 